Monday, Jun 14, 2021 | Last Update : 04:21 AM IST

gilead sciences inc

Gilead prices COVID-19 drug remdesivir at $2,340 per patient in developed nations

Remdesivir is expected to be in high demand as one of the only treatments so far shown to alter the course of COVID-19

30 Jun 2020 11:23 AM

Dr Reddy's inks licensing pact with Gilead Sciences for Remdesivir

Gilead Sciences signed similar non-exclusive licensing agreements with Cipla, Hetero Labs, Jubilant Lifesciences, Mylan and Zydus Cadila

14 Jun 2020 9:59 AM

Despite FDA warning, Trump says he is taking hydroxychloroquine

The Food and Drug Administration has issued a warning about its use

19 May 2020 10:15 AM

ADVERTISEMENT
ADVERTISEMENT